Estrella Immunopharma Gains Momentum with ARTEMIS T-cell Therapy Estrella Immunopharma's proprietary ARTEMIS T-cell platform is showing promise in addressing limitations of traditional CAR-T therapies. The company’s lead candidate, EB103, is progressing through clinical trials, targeting relapsed B-cell malignancies. Analysts highlight its safety and potential to expand patient access, positioning it as a transformative cancer treatment.12